Incannex Healthcare Limited (IXHL)
USD 0.13
(-0.15%)
USD 0.13
(-0.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -5.48 Million USD | 74.61% |
| 2023 | -21.56 Million AUD | 16.41% |
| 2022 | -25.79 Million AUD | -276.33% |
| 2021 | -6.85 Million AUD | -176.86% |
| 2020 | -2.47 Million AUD | -8639.1% |
| 2019 | -28.33 Thousand AUD | 0.26% |
| 2018 | -28.4 Thousand AUD | 73.84% |
| 2017 | -108.6 Thousand AUD | -190.49% |
| 2016 | 120.02 Thousand AUD | -85.32% |
| 2015 | 817.77 Thousand AUD | 54.52% |
| 2014 | 529.24 Thousand AUD | -44.63% |
| 2013 | 955.74 Thousand AUD | 142.71% |
| 2012 | 393.78 Thousand AUD | 377.22% |
| 2011 | 82.51 Thousand AUD | -77.16% |
| 2010 | 361.3 Thousand AUD | -94.24% |
| 2009 | 6.27 Million AUD | 713.28% |
| 2008 | -1.02 Million AUD | 78.75% |
| 2007 | -4.81 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -14.08 Million USD | 34.79% |
| 2024 Q3 | -8.89 Million USD | 36.84% |
| 2024 Q4 | -5.48 Million USD | 61.06% |
| 2023 Q4 | -21.56 Million AUD | 0.0% |
| 2023 FY | -21.56 Million AUD | 16.41% |
| 2023 Q2 | -28.02 Million AUD | 0.0% |
| 2022 Q2 | -19.77 Million AUD | 0.0% |
| 2022 FY | -25.79 Million AUD | -276.33% |
| 2022 Q4 | -37.5 Million AUD | 0.0% |
| 2021 Q2 | -11.84 Million AUD | 0.0% |
| 2021 Q4 | -9.12 Million AUD | 0.0% |
| 2021 FY | -6.85 Million AUD | -176.86% |
| 2020 Q2 | -5.12 Million AUD | 0.0% |
| 2020 FY | -2.47 Million AUD | -8639.1% |
| 2020 Q4 | -3.6 Million AUD | 0.0% |
| 2019 FY | -28.33 Thousand AUD | 0.26% |
| 2019 Q4 | -28.33 Thousand AUD | 0.0% |
| 2019 Q2 | -221.88 Thousand AUD | 0.0% |
| 2018 FY | -28.4 Thousand AUD | 73.84% |
| 2018 Q2 | -465.72 Thousand AUD | 0.0% |
| 2018 Q4 | -28.4 Thousand AUD | 0.0% |
| 2017 FY | -108.6 Thousand AUD | -190.49% |
| 2017 Q4 | -109.45 Thousand AUD | 0.0% |
| 2017 Q2 | -1.52 Million AUD | 0.0% |
| 2016 Q4 | 120.02 Thousand AUD | 300.0% |
| 2016 FY | 120.02 Thousand AUD | -85.32% |
| 2016 Q3 | 30 Thousand AUD | 110.74% |
| 2016 Q2 | -279.32 Thousand AUD | -236.63% |
| 2016 Q1 | 204.44 Thousand AUD | -75.0% |
| 2015 Q1 | 132.31 Thousand AUD | -75.0% |
| 2015 Q4 | 817.77 Thousand AUD | 300.0% |
| 2015 Q2 | 268.1 Thousand AUD | 102.63% |
| 2015 Q3 | 204.44 Thousand AUD | -23.74% |
| 2015 FY | 817.77 Thousand AUD | 54.52% |
| 2014 FY | 529.24 Thousand AUD | -44.63% |
| 2014 Q1 | 238.93 Thousand AUD | -75.0% |
| 2014 Q2 | -393.14 Thousand AUD | -264.54% |
| 2014 Q3 | 132.31 Thousand AUD | 133.65% |
| 2014 Q4 | 529.24 Thousand AUD | 300.0% |
| 2013 FY | 955.74 Thousand AUD | 142.71% |
| 2013 Q4 | 955.74 Thousand AUD | 300.0% |
| 2013 Q3 | 238.93 Thousand AUD | 157.59% |
| 2013 Q2 | -414.92 Thousand AUD | -521.48% |
| 2013 Q1 | 98.44 Thousand AUD | -75.0% |
| 2012 Q2 | -289.54 Thousand AUD | -1503.56% |
| 2012 FY | 393.78 Thousand AUD | 377.22% |
| 2012 Q4 | 393.78 Thousand AUD | 300.0% |
| 2012 Q3 | 98.44 Thousand AUD | 134.0% |
| 2012 Q1 | 20.62 Thousand AUD | -75.0% |
| 2011 Q1 | 83.72 Thousand AUD | -76.83% |
| 2011 Q4 | 82.51 Thousand AUD | 300.0% |
| 2011 FY | 82.51 Thousand AUD | -77.16% |
| 2011 Q3 | 20.62 Thousand AUD | 100.94% |
| 2011 Q2 | -2.19 Million AUD | -2723.16% |
| 2010 Q4 | 361.3 Thousand AUD | 331.53% |
| 2010 Q2 | 6.02 Million AUD | 283.92% |
| 2010 Q1 | 1.56 Million AUD | -75.0% |
| 2010 FY | 361.3 Thousand AUD | -94.24% |
| 2010 Q3 | 83.72 Thousand AUD | -98.61% |
| 2009 Q4 | 6.27 Million AUD | 300.0% |
| 2009 Q3 | 1.56 Million AUD | 615.93% |
| 2009 Q2 | 219.19 Thousand AUD | 185.66% |
| 2009 FY | 6.27 Million AUD | 713.28% |
| 2009 Q1 | -255.88 Thousand AUD | 75.0% |
| 2008 Q2 | -4.07 Million AUD | -238.07% |
| 2008 Q4 | -1.02 Million AUD | -300.0% |
| 2008 FY | -1.02 Million AUD | 78.75% |
| 2008 Q1 | -1.2 Million AUD | 75.0% |
| 2008 Q3 | -255.88 Thousand AUD | 93.72% |
| 2007 FY | -4.81 Million AUD | 0.0% |
| 2007 Q4 | -4.81 Million AUD | -300.0% |
| 2007 Q3 | -1.2 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 105.822% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 107.318% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.26% |
| Cosmos Health Inc. | 8.59 Million USD | 163.848% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 33.22% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.196% |
| Cronos Group Inc. | -663.32 Million USD | 99.173% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 62.359% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 104.5% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -89.045% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 64.918% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 64.918% |
| SCYNEXIS, Inc. | -19.35 Million USD | 71.654% |
| Safety Shot Inc | -2.28 Million USD | -140.109% |
| Theratechnologies Inc. | 24.87 Million USD | 122.054% |
| Alpha Teknova, Inc. | 1.97 Million USD | 377.862% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 2881.313% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.267% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -117.659% |
| Dynavax Technologies Corporation | 106.63 Million USD | 105.144% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.88% |
| Radius Health, Inc. | 359.28 Million USD | 101.527% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 41.833% |
| Alvotech | 1.06 Billion USD | 100.515% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 95.808% |
| SIGA Technologies, Inc. | -148.68 Million USD | 96.311% |
| Shineco, Inc. | 29.29 Million USD | 118.726% |
| Silver Spike Investment Corp. | -32.61 Million USD | 83.181% |
| Journey Medical Corporation | -9.7 Million USD | 43.506% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -8.391% |
| Embecta Corp. | 1.31 Billion USD | 100.418% |
| Harrow Health, Inc. | 116.41 Million USD | 104.712% |
| Procaps Group, S.A. | 242.93 Million USD | 102.258% |
| Biofrontera Inc. | 4.05 Million USD | 235.232% |
| DURECT Corporation | -7.65 Million USD | 28.338% |
| PainReform Ltd. | -7.95 Million USD | 31.006% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 83.64% |
| OptiNose, Inc. | 58.06 Million USD | 109.446% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -5.765% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 136.535% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 5232.932% |
| ProPhase Labs, Inc. | 19.23 Million USD | 128.522% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.206% |
| Procaps Group S.A. | 242.93 Million USD | 102.258% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 249.13% |
| Viatris Inc. | 17.13 Billion USD | 100.032% |
| Rockwell Medical, Inc. | 4.45 Million USD | 223.092% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -12.467% |
| Tilray Brands, Inc. | 158.97 Million USD | 103.45% |
| PetIQ, Inc. | 351.93 Million USD | 101.559% |
| Talphera, Inc. | -5.72 Million USD | 4.125% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 103.094% |
| Alimera Sciences, Inc. | 55.3 Million USD | 109.917% |
| Assertio Holdings, Inc. | -32.52 Million USD | 83.138% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -268.437% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 230.069% |
| Hempacco Co., Inc. | 13.61 Million USD | 140.287% |
| Alvotech | 1.06 Billion USD | 100.515% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 94.328% |
| Kamada Ltd. | -46.43 Million USD | 88.187% |
| Currenc Group, Inc. | -16.57 Million USD | 66.904% |
| Indivior PLC | -33.95 Million USD | 83.845% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 2204.968% |
| Flora Growth Corp. | -713 Thousand USD | -669.285% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 33.22% |
| Evolus, Inc. | 63.7 Million USD | 108.61% |
| HUTCHMED (China) Limited | -197.45 Million USD | 97.222% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.145% |
| Akanda Corp. | 3.9 Million USD | 240.464% |